Flatiron Health today announced their planned presence at the American Society of Hematology (ASH) Annual Meeting and Exposition, including seven accepted abstracts for poster presentation and ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 ...

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

Anas Younes, senior vice president, haematology R&D, AstraZeneca, said: “Our data at ASH from the AMPLIFY phase III trial will demonstrate the efficacy and safety of our leading second-generation BTK ...

It licensed the compound, an anti-CD20 mAb, to London-based GlaxoSmithKline ... Ilaris (canakinumab), an interleukin-1β inhibitor, was fully developed in-house at the Boston headquarters of ...

The US regulator has placed oral BTK inhibitor orelabrutinib on partial ... That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab) that inhibit ...

Evobrutinib was the first BTK inhibitor to show proof-of-concept in ... That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab) – which inhibit ...

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

Antibodies against B cells Rituximab is a depleting antibody directed against CD20 on the surface of B ... risk of infections and malignancies. TNF-inhibitors have several different safety issues ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...